
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
What did industry experts and insiders tell Pharmaceutical Executive at the start of 2026?
Every month, Pharmaceutical Executive speaks with a variety of experts and industry insiders. They provide commentary on current events, insight on trends, and detail the direction they expect the industry to go in the coming months.





